Awarded Contractocds-h6vhtk-0445bc

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024<br/>Offer reference number: CM/PHR/22/5689<br/>CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of fr...

Buyer

NHS England

Value

£832,292,000

Published

20 Aug 2024

Closes

5 Apr 2024

Procurement details

Source

Find a Tender

Region

London

Procurement method

Open

Category

Goods

Contract starts

Not provided

Contract ends

Not provided

CPV classifications

33600000

Pharmaceutical products

Lots

Lot 1 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South - Lot 1

£129,938,000

CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated...

Delivery: United Kingdom

Lot 2 CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South - Lot 2

£644,038,000

CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated...

Delivery: United Kingdom

Lot 3 CM/PHR/22/5689/03 - Omalizumab and Diroximel Fumarate for MAE & NOFE - Lot 3

£58,317,000

CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award...

Delivery: United Kingdom

Documents

No document metadata is available for this public record.

Contains public sector information licensed under the Open Government Licence v3.0.